News

FDA grants breakthrough status to Rett syndrome treatment

A gene therapy showing potential to restore lost developmental milestones in people living with Rett syndrome has earned breakthrough therapy status from the U.S. Food and Drug Administration (FDA). The experimental therapy, TSHA-102, is being developed by Taysha Gene Therapies. A breakthrough therapy designation…

Rett community goes purple in October for awareness month

October is Rett Syndrome Awareness Month, and supporters are going purple to bring attention to the rare genetic condition. “There’s no one right way to raise awareness,” the International Rett Syndrome Foundation (IRSF) says on its website. “Whether you’re posting on social media, sharing your story, or just starting…

Daybue shows real-world benefits for Rett syndrome patients: Study

One year of daily Daybue (trofinetide) treatment led to improvements in behaviors such as nonverbal communication, alertness, and social interaction and connectedness among children and adults with Rett syndrome. That’s according to published interim data from Acadia Pharmaceuticals‘ Phase 4 LOTUS study that assessed the safety and…

Reduced orexin signaling may cause Rett syndrome sleep problems

Reduced production of orexin and its receptors is associated with problems in sleep-wake cycles in a mouse model of Rett syndrome (RTT), a study suggests. Orexin is a signaling molecule that regulates sleep and wakefulness in the brain. While circadian rhythms that regulate the sleep-wake cycle were generally unaffected in…